8-K: Tredegar Reports Improved Fourth Quarter and Full Year 2024 Results Driven by Strong Performance in Aluminum Extrusions and PE Films
Earnings Release
Tredegar Corporation announces improved financial results for Q4 and full year 2024, driven by strong performances in both Aluminum Extrusions and PE Films segments, and the sale of Terphane.
Summary
- Tredegar Corporation reported a net loss from continuing operations of $(7.3) million ($(0.21) per diluted share) for the fourth quarter of 2024, compared to a loss of $(34.1) million ($(1.00) per diluted share) in the fourth quarter of 2023.
- Net income from ongoing operations for Q4 2024 was $2.0 million ($0.06 per diluted share), up from $1.1 million ($0.03 per diluted share) in Q4 2023.
- For the full year 2024, net income from continuing operations was $1.0 million ($0.03 per diluted share), compared to a loss of $(99.2) million ($(2.91) per diluted share) in 2023.
- Net income from ongoing operations for the full year 2024 was $17.2 million ($0.50 per diluted share), compared to a loss of $(2.0) million ($(0.07) per diluted share) in 2023.
- Aluminum Extrusions' EBITDA from ongoing operations was $9.7 million in Q4 2024, compared to $8.0 million in Q4 2023.
- Aluminum Extrusions' sales volume was 35.8 million pounds in Q4 2024, up from 32.9 million pounds in Q4 2023.
- PE Films' EBITDA from ongoing operations was $7.6 million in Q4 2024, compared to $4.5 million in Q4 2023.
- PE Films' sales volume was 9.1 million pounds in Q4 2024, up from 8.5 million pounds in Q4 2023.
- The company completed the sale of Terphane on November 1, 2024, and received additional post-closing settlement proceeds of $9.8 million in Q1 2025.
- Tredegar's net leverage ratio improved significantly to 1.1x at the end of 2024, compared to 3.7x at the end of 2023.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to improved financial results, a stronger balance sheet, and positive outlook for net new orders. However, the goodwill impairment and ongoing risks temper the overall sentiment.
Positives
- Improved financial performance in both Aluminum Extrusions and PE Films segments.
- Significant reduction in net leverage ratio, indicating a stronger balance sheet.
- Successful completion of the sale of Terphane, generating proceeds to pay down debt.
- Increase in net new orders for Aluminum Extrusions, suggesting a recovery in demand.
- Potential benefits from increased Section 232 tariffs on aluminum imports.
- Strong sales volume growth in PE Films, particularly in surface protection films.
Negatives
- The company recognized a special item for the non-cash write-off of goodwill of $13.3 million associated with the Clearfield, Utah operation.
- Net sales for Aluminum Extrusions in 2024 were relatively flat versus 2023.
- Open orders for Aluminum Extrusions are still below pre-pandemic levels.
- Overwrap sales volume in the fourth quarter of 2024 decreased 23% versus a strong volume performance in the fourth quarter of 2023.
Risks
- Macroeconomic factors such as inflation, interest rates, and recession risks could impact the company's performance.
- Increased operating costs, including raw materials and energy, could negatively affect profitability.
- Failure to comply with financial covenants in the ABL Facility could restrict future borrowings.
- Disruptions to manufacturing facilities, including those resulting from labor shortages, could impact production.
- Loss of sales to significant customers could negatively impact the company's business.
- Failure to achieve sales to new customers to replace lost business could hinder growth.
- The actual timing and level of the tariffs remains a fluid situation.
Future Outlook
Net new orders have continued to grow at Bonnell Aluminum so far in 2025, and PE Films results are encouraging.
Management Comments
- Both businesses finished 2024 with solid performances in the typically seasonally low fourth quarter.
- Our balance sheet was strong at the end of 2024 with a net leverage ratio of 1.1x, which was a dramatic improvement from 3.7x at the end of 2023, due to the cyclical recovery underway in our businesses and the completion of the sale of Terphane on November 1, 2024.
- We support actions to increase the Section 232 tariffs on aluminum, to close loopholes that allowed foreign companies to evade the tariffs and to apply the tariffs to downstream products like the extrusions that we produce.
Industry Context
The report highlights the impact of trade cases and tariffs on the aluminum extrusion industry, as well as the cyclical nature of the PE Films business, particularly in relation to the display industry.
Comparison to Industry Standards
- It's difficult to provide a precise comparison to industry standards without knowing the specific sub-sectors Tredegar operates in and the performance of its direct competitors.
- However, the aluminum extrusion industry is generally competitive, with companies like Arconic and Kaiser Aluminum being major players.
- Tredegar's focus on custom aluminum extrusions and surface protection films differentiates it from some of the larger, more diversified players.
- The improvement in net leverage ratio to 1.1x suggests a healthier financial position compared to companies with higher leverage in the same industry.
Legal Proceedings
- The U.S. Aluminum Extruders Coalition has appealed the USITC's negative determination regarding injury from unfairly priced imports of aluminum extrusions.
Stakeholder Impact
- Shareholders will likely react positively to the improved financial performance and stronger balance sheet.
- Employees may benefit from increased job security and potential for incentive compensation.
- Customers may experience improved service and product quality due to investments in productivity projects.
- Suppliers may see increased demand for raw materials as sales volumes grow.
Next Steps
- The company will continue to manage net working capital, capital expenditures, and costs.
- Tredegar will monitor the impact of increased Section 232 tariffs on aluminum imports.
- The company will focus on productivity projects and capital expenditures to support continuity of operations in both Aluminum Extrusions and PE Films segments.
Key Dates
| Date | Description |
|---|---|
| February 2017 | Acquisition of Clearfield, Utah operation (formerly Futura). |
| December 27, 2021 | Completion of the sale of investment interests in kaleo, Inc. |
| October 2022 | The USITC extended existing duties on aluminum extrusions from China for a period of five years. |
| November 2023 | The USITC found a reasonable indication that the American aluminum extrusions industry is materially injured or threatened with injury due to imports from 14 countries, including China. |
| November 3, 2023 | The pension plan termination and settlement process was completed. |
| September 2024 | The USDOC announced its final determinations that aluminum extrusion producers and exporters in 14 countries, including China, sold aluminum extrusions at less-than-fair value in the U.S. |
| October 2024 | The USITC found that U.S. producers had not been materially injured by reason of the subject imports. |
| November 1, 2024 | Completion of the sale of its flexible packaging films business (Terphane) to Oben Group. |
| December 31, 2024 | End of the fourth quarter and full year 2024 reporting period. |
| February 10, 2025 | Section 232 tariffs on all aluminum imports were increased from 10% to 25%, effective March 12, 2025. |
| February 28, 2025 | The Company received $9.8 million from post-closing settlement of the Terphane transaction. |
| March 12, 2025 | Date of the earnings release and increase of Section 232 tariffs on aluminum imports. |
| June 30, 2026 | Maturity date of the $125 million asset-based credit agreement (ABL Facility). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.